PMC is working diligently with Penn Medicine to develop a process for patients and families to learn if Leqembi is a good fit for them and, if it is, how they can safely and effectively receive the medication. We will continue to update the PMC community on our progress.
Later this month, we are also excited to learn more about the results of the Phase 3 study of donanemab. Donanemab is an intravenous anti-amyloid therapy, like lecanemab, for people with early-stage Alzheimer’s disease. Please save the date to attend the virtual PMC Community Discussion on Donanemab on August 14 at 4 p.m. Registration for the Community Discussion will be sent out shortly, and the event will be recorded.
Fortuitously timed with Independence Day, the news of lecanemab‘s full approval signals a revolution in Alzheimer’s disease. The clinicians and staff at PMC will continue to help lead this change and to strive to provide the highest standard of reasonable and necessary care for our patients and their loved ones.
Sincerely,
Jason Karlawish and David Wolk
Penn Memory Center Co-Directors